Biotech · Public company · Houston, TX, US
Marker Therapeutics, Inc.
Ticker MRKR · SEC CIK 0001094038
Track this companyFree. Adds Marker Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials73 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline13
- Adjuvant (GM-CSF) AlonePhase 2 · Platinum Sensitive Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- FRα peptide plus Adjuvant (GM-CSF)Phase 2 · Platinum Sensitive Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- High dose FRα vaccinePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Low dose FRα vaccinePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- MT-401Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- MT-401-OTSPhase 1 · Acute Myeloid Leukemia, in RelapseClinicalTrials.gov · fetched Nov 12, 2026
- MT-601Phase 1 · Non-Hodgkin Lymphoma, AdultClinicalTrials.gov · fetched Nov 12, 2026
- MT-601 dose 1200 million cellsPhase 1 · Pancreas CancerClinicalTrials.gov · fetched Nov 12, 2026
- MT-601 dose 200 million cellsPhase 1 · Pancreas CancerClinicalTrials.gov · fetched Nov 12, 2026
- MT-601 dose 400 million cellsPhase 1 · Pancreas CancerClinicalTrials.gov · fetched Nov 12, 2026
- MT-601 dose 800 million cellsPhase 1 · Pancreas CancerClinicalTrials.gov · fetched Nov 12, 2026
- Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)Respiratory FailureClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic CancerPHASE1 · NOT_YET_RECRUITING · started Jul 16, 2026ClinicalTrials.gov NCT06549751 · fetched Nov 12, 2026
- Safety of MT-401-OTS in Patients With Relapsed AML or MDSPHASE1 · RECRUITING · started Jun 16, 2025ClinicalTrials.gov NCT06552416 · fetched Nov 12, 2026
- Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory LymphomaPHASE1 · RECRUITING · started Jan 2, 2023ClinicalTrials.gov NCT05798897 · fetched Nov 12, 2026
- Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantPHASE2 · TERMINATED · started Oct 14, 2020ClinicalTrials.gov NCT04511130 · fetched Nov 12, 2026
- Plasma Adsorption in Patients With Confirmed COVID-19NA · COMPLETED · started May 20, 2020ClinicalTrials.gov NCT04358003 · fetched Nov 12, 2026
- Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian CancerPHASE2 · TERMINATED · started Jul 20, 2017ClinicalTrials.gov NCT02978222 · fetched Nov 12, 2026
- Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast CancerPHASE2 · COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02593227 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Oct 19, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 19, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 18, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Feb 9, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 5, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 6, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 26, 2025 · fetched Nov 12, 2026
NIH awards10
- Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer PatientsFiscal year 2026 · $645.5KNIH RePORTER 1R01FD008756-01 · fetched Nov 12, 2026
- A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin LymphomaFiscal year 2026 · $665KNIH RePORTER 5R44CA291521-03 · fetched Nov 12, 2026
- Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual DiseaseFiscal year 2025 · $188.7KNIH RePORTER 5R01FD007272-03 · fetched Nov 12, 2026
- Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplantFiscal year 2025 · $664.8KNIH RePORTER 5R44CA285177-03 · fetched Nov 12, 2026
- Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product StrategyFiscal year 2025 · $1.3MNIH RePORTER 5R44CA287653-02 · fetched Nov 12, 2026
- A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin LymphomaFiscal year 2025 · $665KNIH RePORTER 5R44CA291521-02 · fetched Nov 12, 2026
- A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOXFiscal year 2025 · $674.3KNIH RePORTER 5R44CA295168-02 · fetched Nov 12, 2026
- Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product StrategyFiscal year 2024 · $650.7KNIH RePORTER 1R44CA287653-01A1 · fetched Nov 12, 2026
- A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin LymphomaFiscal year 2024 · $665KNIH RePORTER 1R44CA291521-01 · fetched Nov 12, 2026
- A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOXFiscal year 2024 · $674.3KNIH RePORTER 1R44CA295168-01 · fetched Nov 12, 2026